文章摘要
王逸君,张碧云,于大海,吴艳,吴勉华.益髓健脾汤防治直肠癌患者新辅助同期放化疗骨髓抑制的临床研究[J].南京中医药大学学报,2018,34(6):557-560.
益髓健脾汤防治直肠癌患者新辅助同期放化疗骨髓抑制的临床研究
Clinical Study on the Efficacy of Boost Marrow and Fortify Spleen Decoction in Preventing and Treating Myelosuppression of Rectal Cancer Patients with Neoadjuvant Concurrent Chemoradiation
  
DOI:
中文关键词: 关键词:益髓健脾汤  中医药疗法  直肠癌  骨髓抑制
英文关键词: boost marrow and fortify spleen decoction  TCM therapy  rectal cancer  myelosuppression
基金项目:
作者单位
王逸君1,张碧云1*,于大海1,吴艳2,吴勉华2 1.南京中医药大学附属医院江苏 南京 2100292.南京中医药大学第一临床医学院江苏 南京 210023 
摘要点击次数: 353
全文下载次数: 260
中文摘要:
      目的 观察益髓健脾汤防治直肠癌患者新辅助同期放化疗骨髓抑制的临床疗效。方法 2015年10月至2017年10月共入组直肠癌新辅助同期放化疗患者60例,随机分为治疗组及对照组各30例,均行盆腔调强放疗(处方剂量:95%PTV=50 Gy/25次,5次/周,周一至周五),联合同期化疗(卡培他滨片,825 mg/m2,口服,每日2次,放疗日),共5周。治疗组从放化疗开始(研究起点)同时加服益髓健脾汤,疗程至放疗结束后30天(研究终点);对照组仅行同期放化疗。观察2组患者骨髓抑制发生、中医证候和生活质量等情况。结果 治疗组Ⅲ~Ⅳ级骨髓抑制发生率明显低于对照组(P<0.05);重组人粒细胞集落刺激因子(rhG-CSF)使用剂量明显低于对照组(P<0.01);治疗组平均住院时间短于对照组(P<0.05)。2组患者均无Ⅳ级泌尿、消化系统不良反应发生。与对照组相比,研究组的中医证候积分降低(P<0.05);研究终点时治疗组KPS评分稳定率为83.33%,高于对照组(56.67%),P<0.05。结论 益髓健脾汤能显著减少直肠癌新辅助同期放化疗患者骨髓抑制发生率,改善患者治疗后相关中医临床症状,延缓KPS评分下降趋势,提高患者治疗耐受度及生活质量。
英文摘要:
      OBJECTIVE To observe the clinical efficacy of boost marrow and fortify spleen decoction in preventing and treating myelosuppression of rectal cancer patients with neoadjuvant concurrent chemoradiation. METHODS 60 rectal cancer patients with myelosuppression induced by neoadjuvant concurrent chemoradiation from October 2015 to October 2017,were divided into treatment group and control group randomly. All patients completed pelvic intensity-modulated radiation therapy (Prescription dose: 95% PTV = 50 Gy/25 times, five times per week, from Monday to Friday), along with concurrent chemotherapy (Capecitabine tablets; 825 mg/m2, taken orally, twice a day, radiotherapy days), a total of five weeks. The treatment group was treated with boost marrow and fortify spleen decoction. The session was from the beginning of chemoradiation (the starting point of the study) to the 30th day after radiotherapy (the end point of the study). The control group was treated with concurrent chemoradiation. The occurrence of myelosuppression, TCM syndromes, quality of life were observed. RESULTS The incidence of Grade Ⅲ-Ⅳ myelosuppression of the treatment group was obviously lower than that of the control group (P<0.05); The doses of recombinant human granulocyte colony stimulating factor (rhG - CSF) of the treatment group were significantly lower than those of the control group (P<0.01); The average hospitalization time of the treatment group was shorter than that of the control group (P<0.05). There were no adverse reactions occurring like Ⅳ urinary and dyspepsia in both of the two groups. Compared with the control group, the TCM syndrome integral of the treatment group decreased (P<0.05); At the end of the study, the stable rate of KPS score in treatment group was 83.33%, higher than that in control group (56.67%), P<0.05. CONCLUSION Boost marrow and fortify spleen decoction can significantly reduce the incidence of myelosuppression in rectal cancer patients with neoadjuvant concurrent chemoradiation, improve the relevant TCM clinical symptoms after treatment, delay the downward trend of KPS score, as well as make patients' treatment tolerance and quality of life higher, which is worthy of further study.
查看全文   查看/发表评论  下载PDF阅读器
关闭
微信公众号